AU2008231425B2 - Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment - Google Patents
Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment Download PDFInfo
- Publication number
- AU2008231425B2 AU2008231425B2 AU2008231425A AU2008231425A AU2008231425B2 AU 2008231425 B2 AU2008231425 B2 AU 2008231425B2 AU 2008231425 A AU2008231425 A AU 2008231425A AU 2008231425 A AU2008231425 A AU 2008231425A AU 2008231425 B2 AU2008231425 B2 AU 2008231425B2
- Authority
- AU
- Australia
- Prior art keywords
- breast cancer
- allele
- markers
- marker
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 439
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 433
- 230000002068 genetic effect Effects 0.000 title claims abstract description 78
- 238000003745 diagnosis Methods 0.000 title abstract description 42
- 238000012502 risk assessment Methods 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 title description 69
- 238000004393 prognosis Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 163
- 230000001965 increasing effect Effects 0.000 claims abstract description 76
- 230000003247 decreasing effect Effects 0.000 claims abstract description 31
- 108700028369 Alleles Proteins 0.000 claims description 352
- 239000003550 marker Substances 0.000 claims description 244
- 239000000523 sample Substances 0.000 claims description 208
- 102000054766 genetic haplotypes Human genes 0.000 claims description 159
- 206010028980 Neoplasm Diseases 0.000 claims description 117
- 150000007523 nucleic acids Chemical class 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 49
- 108020004707 nucleic acids Proteins 0.000 claims description 49
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 21
- 239000013068 control sample Substances 0.000 claims description 13
- 238000003205 genotyping method Methods 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 230000004224 protection Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 173
- 201000010099 disease Diseases 0.000 description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 75
- 102210006767 rs3803662 Human genes 0.000 description 75
- 239000002253 acid Substances 0.000 description 67
- 230000014509 gene expression Effects 0.000 description 67
- 108020004414 DNA Proteins 0.000 description 65
- 102000004169 proteins and genes Human genes 0.000 description 63
- 201000011510 cancer Diseases 0.000 description 60
- 238000004458 analytical method Methods 0.000 description 58
- 108090000765 processed proteins & peptides Proteins 0.000 description 51
- 238000012360 testing method Methods 0.000 description 51
- 102000004196 processed proteins & peptides Human genes 0.000 description 50
- 239000002773 nucleotide Substances 0.000 description 49
- 125000003729 nucleotide group Chemical group 0.000 description 49
- 229920001184 polypeptide Polymers 0.000 description 49
- 101150008921 Brca2 gene Proteins 0.000 description 48
- 108700020462 BRCA2 Proteins 0.000 description 47
- 102000052609 BRCA2 Human genes 0.000 description 47
- 239000000969 carrier Substances 0.000 description 43
- 238000003556 assay Methods 0.000 description 38
- 230000035772 mutation Effects 0.000 description 38
- 210000000481 breast Anatomy 0.000 description 36
- 238000001514 detection method Methods 0.000 description 35
- 210000000349 chromosome Anatomy 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 239000013615 primer Substances 0.000 description 30
- 239000002987 primer (paints) Substances 0.000 description 30
- 238000009396 hybridization Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 230000037361 pathway Effects 0.000 description 26
- 241001136792 Alle Species 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 235000015107 ale Nutrition 0.000 description 24
- 102000015694 estrogen receptors Human genes 0.000 description 24
- 108010038795 estrogen receptors Proteins 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 238000012216 screening Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 102000054765 polymorphisms of proteins Human genes 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 239000003623 enhancer Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 102000003998 progesterone receptors Human genes 0.000 description 17
- 108090000468 progesterone receptors Proteins 0.000 description 17
- 238000001959 radiotherapy Methods 0.000 description 17
- 230000002596 correlated effect Effects 0.000 description 15
- 230000006798 recombination Effects 0.000 description 15
- 238000005215 recombination Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 12
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 101000679548 Homo sapiens TOX high mobility group box family member 3 Proteins 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 239000004055 small Interfering RNA Substances 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000003657 Likelihood-ratio test Methods 0.000 description 7
- 241000287107 Passer Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102210003522 rs4784227 Human genes 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000002751 oligonucleotide probe Substances 0.000 description 6
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960001603 tamoxifen Drugs 0.000 description 6
- 101150074759 NCS1 gene Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 102100037140 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Human genes 0.000 description 4
- 102000036365 BRCA1 Human genes 0.000 description 4
- 108700010154 BRCA2 Genes Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 4
- 101000740545 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 102100022608 TOX high mobility group box family member 3 Human genes 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000002113 chemopreventative effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 238000012252 genetic analysis Methods 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000009862 primary prevention Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 229940122815 Aromatase inhibitor Drugs 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 241000614261 Citrus hongheensis Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 244000182067 Fraxinus ornus Species 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 3
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- 102100037653 Metalloreductase STEAP3 Human genes 0.000 description 3
- 101710147238 Metalloreductase STEAP3 Proteins 0.000 description 3
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000012098 association analyses Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000013439 planning Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000722946 Acanthocybium solandri Species 0.000 description 2
- 244000202285 Acrocomia mexicana Species 0.000 description 2
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 2
- 101700002522 BARD1 Proteins 0.000 description 2
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 2
- 101150064168 CHEK2 gene Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100437784 Drosophila melanogaster bocks gene Proteins 0.000 description 2
- 208000033640 Hereditary breast cancer Diseases 0.000 description 2
- 241001640034 Heteropterys Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100220617 Homo sapiens CHEK2 gene Proteins 0.000 description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 2
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 2
- 101100247596 Larrea tridentata RCA2 gene Proteins 0.000 description 2
- 241001425930 Latina Species 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 2
- 241001605685 Nepheronia Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010005173 SERPIN-B5 Proteins 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 102100030333 Serpin B5 Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 2
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000011325 biochemical measurement Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 201000007741 female breast cancer Diseases 0.000 description 2
- 201000002276 female breast carcinoma Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 102210010853 rs2193094 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- GTWCNYRFOZKWTL-XQNSMLJCSA-N 2-methyl-6-phytylhydroquinone Chemical compound CC(C)CCCC(C)CCCC(C)CCC\C(C)=C\CC1=CC(O)=CC(C)=C1O GTWCNYRFOZKWTL-XQNSMLJCSA-N 0.000 description 1
- KMEBCRWKZZSRRT-UHFFFAOYSA-N 2-methyl-7h-purine Chemical class CC1=NC=C2NC=NC2=N1 KMEBCRWKZZSRRT-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000478345 Afer Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical group O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241000282706 Ateles Species 0.000 description 1
- 241000395918 Auletes Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- 241001669696 Butis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000036493 Contralateral breast cancer Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 101150105088 Dele1 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 101000995602 Escherichia coli (strain K12) Type II NADH:quinone oxidoreductase Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 230000020172 G2/M transition checkpoint Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000684437 Homo sapiens Selenoprotein M Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 101150080778 INPP5D gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000764773 Inna Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 108010067539 Laburnum alpinum lectin I Proteins 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000203494 Lens culinaris subsp culinaris Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 102220629206 Metalloreductase STEAP3_A184T_mutation Human genes 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 244000234179 Myrtus ugni Species 0.000 description 1
- 235000012093 Myrtus ugni Nutrition 0.000 description 1
- 101150092630 Myt1 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 241000690470 Plantago princeps Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000677647 Proba Species 0.000 description 1
- 241001208007 Procas Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000033722 Rare malignant breast tumor Diseases 0.000 description 1
- 101100108045 Rattus norvegicus Acr gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 101150112372 SAP6 gene Proteins 0.000 description 1
- 102100035175 SEC14-like protein 4 Human genes 0.000 description 1
- 102100023647 Selenoprotein M Human genes 0.000 description 1
- 244000166071 Shorea robusta Species 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 241000966334 Simias Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000593789 Stilbe Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 101800000853 Tachykinin-associated peptide 3 Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101150073789 Tnr gene Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 244000245420 ail Species 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003443 anti-oncogenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- -1 beta-gaiactosidase Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- WEMFUFMJQFVTSW-UHFFFAOYSA-N compositin Natural products CC=C(C)C(=O)OC1CC(O)C2(C)COC3C2C1(C)C1CCC2(C)C(CC=C2C1(C)C3OC(=O)C(C)=CC)c1ccoc1 WEMFUFMJQFVTSW-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000002813 epsilometer test Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 108010035554 ferric citrate iron reductase Proteins 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000011454 long-term hormonal therapy Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- YFBPRJGDJKVWAH-UHFFFAOYSA-N methiocarb Chemical compound CNC(=O)OC1=CC(C)=C(SC)C(C)=C1 YFBPRJGDJKVWAH-UHFFFAOYSA-N 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- RSMUVYRMZCOLBH-UHFFFAOYSA-N metsulfuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)NC1=NC(C)=NC(OC)=N1 RSMUVYRMZCOLBH-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000016044 mixed lobular and ductal breast carcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000012107 replication analysis Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000013058 risk prediction model Methods 0.000 description 1
- 101150103887 rpsJ gene Proteins 0.000 description 1
- 101150039612 rpsK gene Proteins 0.000 description 1
- 101150049069 rpsM gene Proteins 0.000 description 1
- 102220017550 rs118203357 Human genes 0.000 description 1
- 102210007166 rs3112612 Human genes 0.000 description 1
- 102210018275 rs4784223 Human genes 0.000 description 1
- 102200127612 rs6960 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108010066082 tartrate-sensitive acid phosphatase Proteins 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8625 | 2007-03-26 | ||
| IS8625 | 2007-03-26 | ||
| IS8648 | 2007-05-25 | ||
| IS8648 | 2007-05-25 | ||
| PCT/IS2008/000009 WO2008117314A2 (en) | 2007-03-26 | 2008-03-26 | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008231425A1 AU2008231425A1 (en) | 2008-10-02 |
| AU2008231425B2 true AU2008231425B2 (en) | 2014-03-20 |
Family
ID=39563444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008231425A Ceased AU2008231425B2 (en) | 2007-03-26 | 2008-03-26 | Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110117545A1 (enExample) |
| EP (3) | EP2540840A3 (enExample) |
| JP (1) | JP5676245B2 (enExample) |
| KR (1) | KR20090127939A (enExample) |
| CN (1) | CN101874120B (enExample) |
| AU (1) | AU2008231425B2 (enExample) |
| CA (1) | CA2681928A1 (enExample) |
| EA (1) | EA019953B1 (enExample) |
| IL (1) | IL201217A (enExample) |
| MX (1) | MX2009010439A (enExample) |
| NZ (1) | NZ580490A (enExample) |
| WO (1) | WO2008117314A2 (enExample) |
| ZA (1) | ZA200907471B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827314B2 (en) | 2003-12-08 | 2017-11-28 | Mars, Incorporated | Edible compositions which are adapted for use by a companion animal |
| EP2463388B1 (en) | 2005-11-29 | 2017-11-22 | Cambridge Enterprise Limited | Markers for breast cancer |
| CN102144036B (zh) | 2008-07-07 | 2014-07-16 | 解码遗传学私营有限责任公司 | 用于乳腺癌风险评估的遗传变型 |
| JP2012504410A (ja) * | 2008-10-03 | 2012-02-23 | マース インコーポレーテッド | イヌにおける肝臓の銅蓄積についての遺伝子検査およびペット用低銅食餌 |
| EP2438193B1 (en) * | 2009-06-01 | 2015-07-22 | Genetic Technologies Limited | Methods for breast cancer risk assessment |
| US8356023B2 (en) * | 2009-07-28 | 2013-01-15 | Ancestry.Com Operations Inc. | Collaborative systems and methods for constructing representations of data |
| US20140329719A1 (en) * | 2011-06-16 | 2014-11-06 | Illumina, Inc. | Genetic variants for predicting risk of breast cancer |
| GB201120989D0 (en) | 2011-12-06 | 2012-01-18 | Mars Inc | Genetic test |
| KR101390590B1 (ko) * | 2012-06-28 | 2014-04-30 | 서울대학교산학협력단 | 췌장암 재발 예후 예측용 마커 및 이의 용도 |
| EP2968371A4 (en) | 2013-03-12 | 2017-04-12 | The Board of Trustees of the Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| EP3201360A4 (en) * | 2014-09-30 | 2018-05-09 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| US20170286594A1 (en) * | 2016-03-29 | 2017-10-05 | Regeneron Pharmaceuticals, Inc. | Genetic Variant-Phenotype Analysis System And Methods Of Use |
| CN108588263B (zh) * | 2018-06-07 | 2022-02-01 | 中国农业科学院烟草研究所 | 一种用于定位和克隆植物中控制同一性状的双隐性基因的方法 |
| CN108676890B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统 |
| US10395772B1 (en) * | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| AU2019392537A1 (en) | 2018-12-03 | 2021-07-01 | Tempus Ai, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| KR102091790B1 (ko) * | 2019-09-02 | 2020-03-20 | 주식회사 클리노믹스 | 피검사자와 생물체 간의 유전자 정보를 이용한 유전적 띠 제공 시스템 및 그 방법 |
| CA3154157A1 (en) | 2019-09-13 | 2021-03-18 | 23Andme, Inc. | Methods and systems for determining and displaying pedigrees |
| KR20240063050A (ko) * | 2022-11-02 | 2024-05-09 | 주식회사 디시젠 | 암 발생 위험도 예측 방법 |
| CN116287258B (zh) * | 2023-02-23 | 2025-08-26 | 清华大学深圳国际研究生院 | 一种新型分子标志物在乳腺癌诊断或预后评估中的应用 |
| CN119381001A (zh) * | 2025-01-02 | 2025-01-28 | 四川大学华西医院 | 一种乳腺癌复发风险的预测方法、装置、设备及存储介质 |
| CN120805003B (zh) * | 2025-09-04 | 2025-12-02 | 四川大学华西医院 | 一种基于多阶段动态优化的时序数据突变检测方法、系统和存储介质 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5288644A (en) * | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5858659A (en) * | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| US20030170665A1 (en) * | 2001-08-04 | 2003-09-11 | Whitehead Institute For Biomedical Research | Haplotype map of the human genome and uses therefor |
| US20040023237A1 (en) * | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
| PL214402B1 (pl) * | 2003-08-11 | 2013-07-31 | Tomasz Byrski | Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika |
| US9157122B2 (en) * | 2004-11-11 | 2015-10-13 | Garvan Institute Of Medical Research | Method of diagnosing cancer and reagents therefor |
| KR101138862B1 (ko) * | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
| KR101206028B1 (ko) * | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
| US7858303B2 (en) * | 2005-03-14 | 2010-12-28 | Wisconsin Alumni Research Foundation | Method of analyzing breast cancer susceptibility and resistance |
| WO2006121991A2 (en) * | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
-
2008
- 2008-03-26 EP EP12153875.5A patent/EP2540840A3/en not_active Withdrawn
- 2008-03-26 EA EA200970891A patent/EA019953B1/ru not_active IP Right Cessation
- 2008-03-26 KR KR1020097022257A patent/KR20090127939A/ko not_active Ceased
- 2008-03-26 CA CA002681928A patent/CA2681928A1/en not_active Abandoned
- 2008-03-26 MX MX2009010439A patent/MX2009010439A/es active IP Right Grant
- 2008-03-26 JP JP2010500445A patent/JP5676245B2/ja not_active Expired - Fee Related
- 2008-03-26 NZ NZ580490A patent/NZ580490A/xx not_active IP Right Cessation
- 2008-03-26 AU AU2008231425A patent/AU2008231425B2/en not_active Ceased
- 2008-03-26 EP EP12153902.7A patent/EP2527466A3/en not_active Withdrawn
- 2008-03-26 WO PCT/IS2008/000009 patent/WO2008117314A2/en not_active Ceased
- 2008-03-26 CN CN200880016394.2A patent/CN101874120B/zh not_active Expired - Fee Related
- 2008-03-26 EP EP08720170A patent/EP2137324A2/en not_active Withdrawn
- 2008-03-26 US US12/302,473 patent/US20110117545A1/en not_active Abandoned
-
2009
- 2009-09-29 IL IL201217A patent/IL201217A/en not_active IP Right Cessation
- 2009-10-23 ZA ZA2009/07471A patent/ZA200907471B/en unknown
Non-Patent Citations (5)
| Title |
|---|
| Nexo B A et al. CARCINOGENESIS, 2003, vol. 24, no. 5, pages 899-904 * |
| Rio P G et al. INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, vol. 13, no. 4, pages 849-853 * |
| Silva Jose et al. CANCER LETTERS, 1999, vol. 138, no. 1-2, pages 209-215 * |
| Stacey S N et al.PLOS MEDICINE, 2006, vol. 3, no. 7, page e217 * |
| Yamagata Z et al. AMERICAN JOURNAL OF HUMAN GENETICS, 1997, vol. 61, no. 4, page A.388 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA019953B1 (ru) | 2014-07-30 |
| WO2008117314A3 (en) | 2008-12-18 |
| MX2009010439A (es) | 2009-10-20 |
| AU2008231425A1 (en) | 2008-10-02 |
| JP2010522555A (ja) | 2010-07-08 |
| NZ580490A (en) | 2012-08-31 |
| US20110117545A1 (en) | 2011-05-19 |
| IL201217A (en) | 2014-03-31 |
| ZA200907471B (en) | 2014-03-26 |
| WO2008117314A2 (en) | 2008-10-02 |
| EP2540840A2 (en) | 2013-01-02 |
| IL201217A0 (en) | 2010-05-31 |
| KR20090127939A (ko) | 2009-12-14 |
| EA200970891A1 (ru) | 2010-04-30 |
| EP2527466A3 (en) | 2013-05-15 |
| EP2527466A2 (en) | 2012-11-28 |
| CN101874120B (zh) | 2015-01-14 |
| EP2540840A3 (en) | 2013-05-15 |
| EP2137324A2 (en) | 2009-12-30 |
| CN101874120A (zh) | 2010-10-27 |
| CA2681928A1 (en) | 2008-10-02 |
| JP5676245B2 (ja) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008231425B2 (en) | Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| EP2329037B1 (en) | Genetic variants predictive of cancer risk | |
| AU2007310412B2 (en) | Cancer susceptibility variants on Chr8q24.21 | |
| US8580501B2 (en) | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| US8865400B2 (en) | Genetic variants contributing to risk of prostate cancer | |
| AU2009269540A1 (en) | Genetic variants predictive of cancer risk in humans | |
| EP2313525A2 (en) | Genetic variants for breast cancer risk assessment | |
| JP2011530306A (ja) | 甲状腺癌のリスクアセスメントに有用な遺伝的変異 | |
| WO2010128530A1 (en) | Genetic variants contributing to risk of prostate cancer | |
| WO2010131268A1 (en) | Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |